Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. Alkem Laboratories was founded in 1973. Alkem Laboratories is headquartered in Mumbai, India. Alkem Laboratories has 21,057 total employees.
Leading Pharmaceutical company Alkem Laboratories holds a 4.1% market share in the Indian domestic formulation market as of 9M FY25, making it the 5th largest pharmaceutical company in India. The company maintains its #1 position in anti-infectives and has a strong presence in gastrointestinal, pain management, vitamins, minerals, and nutrients segments while also expanding in chronic therapies like neurology, cardiology, and diabetology.
It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market.
Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company's product portfolio includes brands, such as Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Taxim, Gemcal, Pipzo and Ondem.
As of March 2025, Alkem Laboratories Ltd has a market capitalisation of Rs 59,331 crore. The company's financial performance in recent quarters demonstrates mixed results with notable margin improvements.
• **Q4 FY25 Revenue**: The revenue for Alkem Laboratories Ltd in the Q4 results 2024 was ₹3,289.71Cr.
• **Q4 FY25 Net Profit**: The net profit for Alkem Laboratories Ltd in the Q4 results 2024 was ₹305.86Cr.
• **FY24 Performance**: For the year ended 2024, Alkem Laboratories Ltd had posted a profit of Rs 1,811.46 crore on a total income of Rs 12,667.58 crore.
• **H1 FY25 Net Profit**: Net Profit (H1 FY25): 12,338 million with a 36% year-over-year growth.
• **H1 FY25 EBITDA**: EBITDA (H1 FY25): 13,615 million with a margin of 21.1% (up from 17.7% in H1 FY24).
Industry Position: Achieved second rank in the Indian Pharmaceutical Market (IPM). The company's domestic operations continue to be a significant growth driver, though it faces challenges in certain therapeutic segments. Alkem Laboratories Ltd (BOM:539523) lagged behind market growth in key therapies like anti-infectives, gastro, pain, and cardiac in Q2. The acute market, which constitutes a significant portion of the company's business, has shown sluggish growth, impacting overall performance.
Promoter holding in Alkem Laboratories Ltd has gone down to 55.13 per cent as of Mar 2025 from 56.38 per cent as of Jun 2024. This slight decline in promoter holding indicates some changes in the ownership structure while maintaining strong promoter control.
The company has a significant international presence, particularly in the United States market. However, The company faced supply chain challenges in the US, resulting in lost contracts and penalties due to inability to supply products. There is ongoing litigation related to the launch of certain products in the US, which could delay market entry and impact revenue.
Despite these challenges, The plant is progressing as planned, with expected production to begin between Q4 and Q1 of next year. We have started receiving orders and queries, indicating positive momentum.
As of May 2025, the company's key investment metrics include:
• **52-Week High**: The highest price of Alkem Laboratories Ltd stock is ₹6,439.90 in the last 52-week.
• **52-Week Low**: The 52-week low price of Alkem Laboratories Ltd (ALKEM) is Rs 4,407.05
• **PE Ratio**: The current PE ratio of Alkem Laboratories Ltd (ALKEM) is 29.35.
• **PB Ratio**: The current PB ratio of Alkem Laboratories Ltd (ALKEM) is 5.50.
The company's management remains optimistic about future growth prospects. Despite this, we maintain our guidance of 8% to 9% growth for the domestic market, expecting H2 to be stronger. The focus remains on margin improvement and strategic expansion in both domestic and international markets.
Alkem Laboratories continues to be a significant player in the Indian pharmaceutical industry, with strong market positions in key therapeutic areas and ongoing efforts to expand its global footprint while managing operational challenges across different markets.
